Ezetimibe: an Update on Its Clinical Usefulness in Specific Patient Groups

Overview

Journal Ther Adv Chronic Dis

Publisher Sage Publications

Date 2017 Feb 17

PMID 28203346

Citations 26

Authors

Daniel Hammersley

Mark Signy

Affiliations

Soon will be listed here.

Abstract

The aim of pharmacological lipid modification is to reduce low-density lipoprotein cholesterol (LDL-C) as a means of either secondary or primary prevention of cardiovascular disease. Statins are the first-line therapy for pharmacological lipid modification. Ezetimibe is a drug which reduces LDL-C by selectively inhibiting intestinal cholesterol absorption. This provides an alternative pharmacological approach to that of statin therapy to reduce LDL-C. Ezetimibe has been shown to significantly reduce levels of LDL-C and recently, as demonstrated in the IMPROVE-IT trial, to reduce the rate of cardiovascular events in high-risk patients. Ezetimibe therefore has an important role in pharmacological lipid modification. In this paper, we examine the body of research behind ezetimibe and assess its current clinical applications in different patient subgroups.

Citing Articles

Ten-year trends in lipid management among patients after myocardial infarction in South Korea.

Oh S, Cho K, Kim M, Sim D, Hong Y, Kim J PLoS One. 2024; 19(10):e0304710.

PMID: 39361921 PMC: 11449489. DOI: 10.1371/journal.pone.0304710.

2024 Egyptian consensus statement on the role of non-statin therapies for LDL cholesterol lowering in different patient risk categories.

El Din Taha H, Kandil H, Badran H, Farag N, Khamis H, Nasr G Egypt Heart J. 2024; 76(1):131.

PMID: 39302613 PMC: 11415330. DOI: 10.1186/s43044-024-00562-7.

Are We Using Ezetimibe As Much As We Should?.

Manolis A, Manolis T, Mikhailidis D, Manolis A Biomark Insights. 2024; 19:11772719241257410.

PMID: 38827240 PMC: 11143858. DOI: 10.1177/11772719241257410.

Atherosclerotic cardiovascular disease landscape in Singapore.

Sia C, Simon O, Loh P, Poh K Front Cardiovasc Med. 2024; 11:1342698.

PMID: 38720921 PMC: 11076755. DOI: 10.3389/fcvm.2024.1342698.

Knowledge mapping of B cell and atherosclerosis over the past 20 years: A bibliometric analysis.

Cheng T, You Y, Jia B, Wang H, Lv M, Zhu X Hum Vaccin Immunother. 2023; 19(3):2277567.

PMID: 37953301 PMC: 10760366. DOI: 10.1080/21645515.2023.2277567.

References

Miettinen T, Gylling H, Strandberg T, Sarna S . Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ. 1998; 316(7138):1127-30. PMC: 28514. DOI: 10.1136/bmj.316.7138.1127. View

Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano A . 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by.... Eur Heart J. 2016; 37(29):2315-2381. PMC: 4986030. DOI: 10.1093/eurheartj/ehw106. View

Catapano A, Reiner Z, De Backer G, Graham I, Taskinen M, Wiklund O . ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011; 217(1):3-46. DOI: 10.1016/j.atherosclerosis.2011.06.028. View

Lipinski M, Benedetto U, Escarcega R, Biondi-Zoccai G, Lhermusier T, Baker N . The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J. 2015; 37(6):536-45. DOI: 10.1093/eurheartj/ehv563. View

Wohl D, Waters D, Simpson Jr R, Richard S, Schnell A, Napravnik S . Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2008; 47(8):1105-8. PMC: 5909814. DOI: 10.1086/592116. View

Pedersen T, Faergeman O, Kastelein J, Olsson A, Tikkanen M, Holme I . High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005; 294(19):2437-45. DOI: 10.1001/jama.294.19.2437. View

Robinson J, Farnier M, Krempf M, Bergeron J, Luc G, Averna M . Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16):1489-99. DOI: 10.1056/NEJMoa1501031. View

Cannon C, Blazing M, Giugliano R, McCagg A, White J, Theroux P . Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372(25):2387-97. DOI: 10.1056/NEJMoa1410489. View

Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K . Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol. 2015; 66(5):495-507. DOI: 10.1016/j.jacc.2015.05.065. View

10.

Shepherd J, Cobbe S, Ford I, Isles C, LORIMER A, Macfarlane P . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20):1301-7. DOI: 10.1056/NEJM199511163332001. View

11.

Hu M, Cheung B, Tomlinson B . Safety of statins: an update. Ther Adv Drug Saf. 2014; 3(3):133-44. PMC: 4110822. DOI: 10.1177/2042098612439884. View

12.

Cannon C, Braunwald E, McCabe C, Rader D, Rouleau J, Belder R . Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350(15):1495-504. DOI: 10.1056/NEJMoa040583. View

13.

Silbernagel G, Chapman M, Genser B, Kleber M, Fauler G, Scharnagl H . High intestinal cholesterol absorption is associated with cardiovascular disease and risk alleles in ABCG8 and ABO: evidence from the LURIC and YFS cohorts and from a meta-analysis. J Am Coll Cardiol. 2013; 62(4):291-9. DOI: 10.1016/j.jacc.2013.01.100. View

14.

Kastelein J, Akdim F, Stroes E, Zwinderman A, Bots M, Stalenhoef A . Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358(14):1431-43. DOI: 10.1056/NEJMoa0800742. View

15.

Keys A, Menotti A, ARAVANIS C, Blackburn H, Djordevic B, BUZINA R . The seven countries study: 2,289 deaths in 15 years. Prev Med. 1984; 13(2):141-54. DOI: 10.1016/0091-7435(84)90047-1. View

16.

Davidson M, McGarry T, Bettis R, Melani L, Lipka L, LeBeaut A . Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002; 40(12):2125-34. DOI: 10.1016/s0735-1097(02)02610-4. View

17.

Serban M, Banach M, Mikhailidis D . Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. Expert Opin Pharmacother. 2015; 17(3):369-80. DOI: 10.1517/14656566.2016.1118055. View

18.

Banach M, Nikolic D, Rizzo M, Toth P . IMPROVE-IT: what have we learned?. Curr Opin Cardiol. 2016; 31(4):426-33. DOI: 10.1097/HCO.0000000000000305. View

19.

Morrone D, Weintraub W, Toth P, Hanson M, Lowe R, Lin J . Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012; 223(2):251-61. DOI: 10.1016/j.atherosclerosis.2012.02.016. View

20.

Baigent C . Cholesterol metabolism and statin effectiveness in hemodialysis patients. J Am Coll Cardiol. 2015; 65(21):2299-301. DOI: 10.1016/j.jacc.2015.04.009. View